Can-Fite BioPharma Ltd. (CANF) Form 6-K — Nov 9, 2026
Can-Fite BioPharma announced that a patient with advanced liver cancer from its completed Phase II Namodenoson study has reached ten years of overall survival and remains cancer-free. The company called the decade-long outcome exceptional for advanced hepatocellular carcinoma, following a nine-year survival report in November 2025. Namodenoson is now in a randomized, blinded pivotal Phase III study in advanced HCC with Child-Pugh B7 cirrhosis. On September 2, 2026, the company said overall survival across the pooled blinded population appeared longer than anticipated, prompting evaluation of an earlier interim analysis; treatment-specific efficacy will only be known at that analysis.
Key figures
- Prior survival report
- nine-year survival announced November 2025
- Patients dosed to date
- over 1,700 in clinical studies
- Phase3 interim analysis
- timing under earlier evaluation per September 2, 2026 announcement
- Survival milestone years
- 10
- Piclidenoson interim enrollment
- first 247 patients enrolled
- Piclidenoson interim data expected
- Q1 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.